Pulse 探索 nav.journalClub 辩论趋势研究者期刊

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

首页探索 nav.journalClub 趋势

⌘+K

Clinical Insights Into CASPR1 and CASPR1/Contactin-1 Complex Autoimmune Nodopathies. | Synapse

February 9, 20260 citations

View Full Paper

Clinical Insights Into CASPR1 and CASPR1/Contactin-1 Complex Autoimmune Nodopathies.

NPNaveen Kumar Paramasivan EBEati Basal RLReghann Lafrance-Corey

Key Points

This research aims to explore the characteristics and treatment responses of CASPR1 and CASPR1/Contactin-1 complex autoimmune nodopathies.
Analyzed the clinical progression of CASPR1-IgG and CASPR1/CNTN1-complex-IgG neuropathies.
Compared the progression with NF155-IgG4 nodopathies.
Evaluated treatment responses to IVIg and rituximab.
CASPR1-IgG neuropathies show faster progression compared to NF155-IgG4 nodopathies.
Some CASPR1/CNTN1-complex-IgG nodopathies result in greater long-term disability.
Both CASPR1 variants are often refractory to IVIg but responsive to rituximab.

Abstract

CASPR1-IgG and CASPR1/CNTN1-complex-IgG neuropathies, though rare, usually have a rapidly progressive course. Both are frequently IVIg-refractory and respond to rituximab. Compared with NF155-IgG4 nodopathies, CASPR1-IgG exhibits faster progression, while some CASPR1/CNTN1-complex-IgG nodopathies can cause greater long-term disability.

问 AI

Like

Bookmark

Share

View Full Paper

Cite This Study

Paramasivan et al. (Tue,) studied this question.

synapsesocial.com/papers/698979e9f0ec2af6756e7eb4 https://doi.org/https://doi.org/10.1212/wnl.0000000000214403

问 AI

Like

Bookmark

Share

View Full Paper